{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000359","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.339984+00:00","generated_at":"2026-06-25T11:59:43.782526+00:00","sec_items":["3.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent","bullets":["Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.","KCL Therapeutics subsidiary awarded U.S. Patent No. 11,324,719 for small molecule NR2F6 agonists/antagonists.","Shares issued under Section 4(a)(2) exemption without underwriters or general solicitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000359","json":"https://secwatch.observer/filing/0001607062-22-000359.json","markdown":"https://secwatch.observer/filing/0001607062-22-000359.md","text":"https://secwatch.observer/filing/0001607062-22-000359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/0001607062-22-000359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/rgbp051622form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T11:59:43.782526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}